Comparative Pharmacology
Head-to-head clinical analysis: BYDUREON BCISE versus FORTAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYDUREON BCISE versus FORTAMET.
BYDUREON BCISE vs FORTAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BYDUREON BCISE (exenatide extended-release) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It activates the GLP-1 receptor, increasing glucose-dependent insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and promoting satiety.
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Subcutaneous injection, 2 mg once weekly.
Initial: 500 mg orally twice daily or 1000 mg orally once daily; titrate in increments of 500 mg weekly; maximum daily dose: 2000 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 2.4 hours after subcutaneous administration, but the extended-release formulation provides prolonged exposure over 2 weeks via continuous release from microspheres.
Terminal elimination half-life is approximately 6.2 hours (range 4–9 hours) in patients with normal renal function; half-life is prolonged in renal impairment (up to 18 hours in moderate impairment and 24 hours in severe impairment).
Excreted primarily via renal degradation; no significant biliary or fecal excretion. Approximately 70% of the dose is eliminated as intact exenatide via glomerular filtration and proteolytic catabolism.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; the remainder is excreted fecally (via bile).
Category C
Category C
Antidiabetic
Antidiabetic